Pathophysiology of antiphospholipid antibodies

Netherlands Journal of Medicine

Volumn 62, Issue 8, 2004, Pages 267-272

  de Groot, P G ^a   Derksen, R H W M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; DISEASE MARKER; HUMAN; IMMUNOPATHOGENESIS; IN VITRO STUDY; NONHUMAN; PATHOPHYSIOLOGY; RISK ASSESSMENT; THROMBOEMBOLISM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION TESTS; GLYCOPROTEINS; HUMANS; RISK FACTORS; THROMBOEMBOLISM;

EID: 7244248669     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Roubey RA. Update on antiphospholipid antibodies. Curr Opin Rheumatol 2000;12:74-8.
2. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003;1:931-42.
3. De Groot PG, Oosting JD, Derksen RHWM. Antiphospholipid antibodies: specificity and pathophysiology. Baillieres Clin Haematol 1993;6:691-709.
4. 2-glycoprotein I. Proc Natl Acad Sci USA 1990;87:4120-4.
5. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Breda-Vriesman PJC, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990;335:1544-7.
6. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;336:177-8.
7. Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001;276:13817-21.
8. Lockshin MD. Prognosis and future directions. In: Hughes syndrome, Khamashta MA (editor). London: Springer Verlag 2000. p. 459-62.
9. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev 2003;2:86-93.
10. Hoeg JM, Segal P, Gregg RE, Chang YS, Lindgren FT, Adamson GL, et al. Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency. The fasting plasma lipids, lipoproteins, and apolipoproteins were evaluated in 5 subjects. Atherosclerosis 1985;55:25-34.
11. 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992;67:649-53.
12. 2-Glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999; 81:87-95.
13. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, et al. Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol 1999;115:214-9.
14. Chamley LW, Allen JL, Johnson PM. Synthesis of beta2 glycoprotein 1 by the human placenta. Placenta 1997;18:403-10.
15. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Pini C, et al. Serum anti-beta2-glycoprotein I antibodies from patients with anti-phospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998;11:425-9.
16. 2-glycoprotein I. Proc Natl Acad Sci USA 1991;81:3640-4.
17. 2-glycoprotein I. Biochem J 1991;277:387-91.
18. Haupt H, Schwick HG, Storiko K. On a hereditary beta-2-glycoprotein I deficiency]. Humangenetik 1968;5:291-3.
19. 2-glycoprotein I deficiency: Prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000;152:337-46.
20. Bork P, Downing AK, Kieffer B, Campbell ID. Structure and distribution of modules in extracellular proteins. Q Rev Biophys 1996;29:119-67.
21. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999;18:5166-74.
22. 2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999;18:6228-31.
23. 2-glycoprotein I) is crucial for cardiolipin binding. Eur J Biochem 2000;267:1770-6.
24. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
25. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, anti-prothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.
26. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001;113:621-9.
27. Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun 2000;15:101-6.
28. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, De Moerloose P, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group Thromb Haemost 2002;88:66-73.
29. Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001;86:575-83.
30. Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest 1997;99:2260-8.
31. George J, Gilburd B, Hojnik M, Levy Y, Langevitz P, Matsuura E, et al. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 1998;160:3917-23.
32. Xang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol 1995;155:1629-36.
33. Cheng-De Y, Shun-Le C, Nan S, Ming O, Feng X. Detection of anti-recombinant beta 2-glycoprotein I and anti-recombinant beta 2-glycoprotein I fifth domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 1998;18:5-10.
34. Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999;96:5164-8.
35. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998;95:15542-6.
36. Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002;169:7097-103.
37. 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996;35:13833-42.
38. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998;79:79-86.
39. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954-60.
40. Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster Blood 2003;101:157-62.
41. 2-glycoprotein I antibody complexes. J Biol Chem 2001;276:3060-7.
42. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1 and II. Thromb Haemost 1996;76:651-2 and 824-34.
43. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000;1477:349-60.
44. Gennari L, Blanco A, Alberto MF, Grosso S, Lazzari MA. The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein I antibodies could be associated with acquired activated protein C resistance in non-systemic lupus erythematosus patients. Br J Haematol 2003;121:527-9.
45. Safa O, Hensley K, Smirnov MD, Esmon CT, Esmon NL. Lipid oxidation enhances the function of activated protein C J Biol Chem 2001;276:1829-36.
46. 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003;278:33831-8.
47. Raschi E, Testoni C, Bosisio D, Borghi MO, Koike T, Mantovani A, et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003;101:3495-500.
48. Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000;275:15541-8.
49. Wang SX, Sun YT, Sui SF. Membrane induced conformational changes in human apolipiprotein H. Biochem J 2000;348:103-6.